Iskanje po repozitoriju

A+ | A- | | SLO | ENG

Povzetek: Uncommon responses during immunotherapy is a new challenging issue in oncology practice. Recently, new criteria for evaluation of response to immunotherapy immune response evaluation criteria solid tumors (iRECIST) were accepted. According to iRECIST, worsening of performance status (PS) accompanied to pseudoprogression reflects most probably the true progression of the malignant disease. Methods. A systematic review of the literature was made by using several electronic database with the following search criteria: symptomatic pseudoprogression, atypical response, immunotherapy and lung cancer. Results. In the literature, we identified five reports of seven patients treated with immunotherapy that met the inclusion criteria. We also report our experience of patient with pseudoprogression and almost complete response after one dose of immunotherapy. Conclusions. As seen from our review, iRECIST criteria might be insufficient in distinguishing true progression from pseudoprogression in some patients with advanced NSCLC treated with immunotherapy. More precise assessment methods are urgently needed.
Ključne besede: symptomatic pseudoprogression, atypical response, immunotherapy, lung cancer
Objavljeno v DiRROS: 11.06.2024; Ogledov: 32; Prenosov: 7
Celotno besedilo (426,11 KB)

Povzetek: Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported. Patients and methods A total of 102 patients with stage III NSCLC treated between September 2005 and November 2010 with induction chemotherapy and CCRT were included in this long term survival analysis. All patients were tested for PD-L1 status and expression of PD-L1 was correlated with overall survival (OS), progression free survival (PFS) and toxicities. Results The median OS of all patients was 24.8 months (95% CI 18.7 to 31.0) with 10 year-survival rate of 11.2%. The median OS of patients with PD-L1 expression was 12.1 months (95% CI 0.1 to 26.2), while in patients with negative or unknown PD-L1 status was significantly longer, 25.2 months (95% CI 18.9 to 31.6), p = 0.005. The median PFS of all patients was 16.4 months (95% CI 13.0 to 19.9). PFS of patients with PD-L1 expression was 10.1 months (95% CI 0.1 to 20.4) and in patients with negative or unknown PD-L1 status was 17.9 months (95% CI 14.2 to 21.7), p = 0.003. Conclusions 10-year overall survival of stage III NSCLC patients after CCRT is 11.2%. PFS and OS differ with regard to PD-L1 status and are significantly shorter for patients with PD-L1 expression. New treatment with check-point inhibitors combined with RT therefore seems reasonable strategy to improve these results.
Ključne besede: NSCLC, non-small cell lung cancer, locally advanced, immunotherapy, chemoradiotherapy
Objavljeno v DiRROS: 10.06.2024; Ogledov: 46; Prenosov: 35
Celotno besedilo (500,20 KB)
Gradivo ima več datotek! Več...

Povzetek: This Collective Article presents information about 30 species with records in eight countries (Greece, Israel, Italy, Montenegro, Slovenia, Spain, Syria and Türkiye) and six ecoregions extending from the Alboran to the Levantine Seas. The recorded species belong to eight Phyla (4 Chlorophyta, 1 Rhodophyta, 1 Porifera, 3 Cnidaria, 2 Platyhelminthes, 2 Arthropoda, 2 Mollusca and 15 Chordata) as follows: Chlorophyta: Didymosporangium repens, Ochlochaete hystrix and Phaeophila hirsuta are reported for the first time from the Aegean coasts of Türkiye and Penicillus capitatus is firstly recorded in Slovenian coastal waters; Rhodophyta: Ptilophora dentata is recorded for the first time in Turkish coasts, from the entrance of a marine cave; Porifera: Tethya meloni is reported from Montenegrin waters; Cnidaria: Savalia savaglia and Dendrophyllia ramea are firstly observed north of the Almeria-Oran front in the southeastern Iberian Peninsula, while Spinimuricea cf. atlantica is firstly recorded in the Gulf of Lion constituting the easternmost record of the species in the Mediterranean Sea; Platyhelminthes: the polyclad flatworms Thysanozoon brocchii and Planocera graffi are reported for the first time from Greek waters, observed inside marine caves; Mollusca: Ascobulla fragilis is firstly reported from the Eastern Levantine Sea while the blanket octopus Tremoctopus violaceus is recorded in Izmir Bay constituting its fifth sighting in the Aegean Sea after a quarter of a century; Arthropoda: the copepod Ditrychocorycaeus africanus is firstly recorded in the Ionian Sea while the tufted ghost crab Ocypode cursor is detected further north in the Tyrrhenian Sea; Chordata: the bothid flounder Arnoglossus grohmanni is firstly reported in Spain while specimens of the rare bythitid Bellottia apoda are presented for the Adriatic Sea; the chondrichthyans Chimaera monstrosa, Dalatias licha, Heptranchias perlo, Leucoraja circularis, Mustelus mustelus, Oxynotus centrina, Squatina aculeata and Torpedo marmorata are presented as collected within 13 continuous years in the bathyal zone of the Antalya Bay; the speleophilic fish Grammonus ater is firstly recorded in the Alboran Sea, observed in a marine cave; the critically endangered sandy ray Leucoraja circularis is reported from the eastern Ionian Sea; the crested oarfish Lophotus lacepede is reported for the first time from Sardinia, based on evidence dating back 20 years; the white trevally Pseudocaranx dentex is firstly recorded in Tremiti Islands (Adriatic Sea, Italy) while the phaeton dragonet Synchiropus phaeton and the gobid Zebrus pallaoroi are firstly reported from Syrian and Italian waters, respectively.
Ključne besede: Mediterranean Sea, rare species, flora, fauna
Objavljeno v DiRROS: 03.06.2024; Ogledov: 111; Prenosov: 81
Celotno besedilo (7,52 MB)
Gradivo ima več datotek! Več...

Povzetek: Gongolaria barbata plays a crucial role as a habitat-forming Fucales species in the Mediterranean Sea, thriving in shallow, sheltered coastal regions, where it exhibits optimal growth in a temperature range of 10 to 25 °C. In the northern Adriatic Sea, a semi-enclosed part of the Mediterranean, there has been a remarkable increase in seawater temperatures in recent decades, often exceeding 28 °C in summer. These high temperatures pose a significant threat to the vulnerable early life stages of G. barbata. This study delves into the effects of four temperatures (15, 18, 24, and 28 °C) on the growth of G. barbata over its first 16 days, closely monitoring mortality, deformities, and overall survival. Our experiments reveal that higher temperatures can result in deformities and increased mortality of germlings. Notably, a temperature of 28 °C resulted in the death of all germlings within the first week, whereas those exposed to 24 °C survived until the second week, albeit with significant deformities prior to death. In contrast, germlings cultivated at 15 and 18 °C exhibited normal development with minimal deformities. These results highlight the susceptibility of the early life stages of G. barbata to temperature-induced stress and provide valuable insights into the potential consequences of rising seawater temperatures in the Mediterranean.
Ključne besede: sea ​​temperature, early stages of growth, deformations, macroalgae, climate change, Mediterranean Sea
Objavljeno v DiRROS: 17.05.2024; Ogledov: 161; Prenosov: 258
Celotno besedilo (2,43 MB)
Gradivo ima več datotek! Več...

Povzetek: Metastatic colorectal cancer (mCRC) is mainly a disease of elderly, however, geriatric population is underrepresented in clinical trials. Patient registries represent a tool to assess and follow treatment outcomes in this patient population. The aim of the study was with the help of the patients% register to determine the safety and efficacy of bevacizumab plus chemotherapy in elderly patients who had previously untreated metastatic colorectal cancer. Patients and methods. The registry of patients with mCRC was designed to prospectively evaluate the safety and efficacy of bevacizumab-containing chemotherapy as well as selection of patients in routine clinical practice. Patient baseline clinical characteristics, pre-specified bevacizumab-related adverse events, and efficacy data were collected, evaluated and compared according to the age categories. Results. Between January 2008 and December 2010, 210 patients with mCRC (median age 63, male 61.4%) started bevacizumab-containing therapy in the 1st line setting. Majority of the 210 patients received irinotecan-based chemotherapy (68%) as 1st line treatment and 105 patients (50%) received bevacizumab maintenance therapy. Elderly (% 70 years) patients presented 22.9% of all patients and they had worse performance status (PS 1/2, 62.4%) than patients in < 70 years group (PS 1/2, 35.8%). Difference in disease control rate was mainly due to inability to assess response in elderly group (64.6% in elderly and 77.8% in < 70 years group, p = 0.066). The median progression free survival was 10.2 (95% CI, 6.7%16.2) and 11.3 (95% CI, 10.2%12.6) months in elderly and < 70 years group, respectively (p = 0.58). The median overall survival was 18.5 (95% CI, 12.4%28.9) and 27.4 (95% CI, 22.7%31.9) months for elderly and < 70 years group, respectively (p = 0.03). Three-year survival rate was 26% and 37.6% in elderly vs. < 70 years group (p = 0.03). Overall rates of bevacizumab-related adverse events were similar in both groups: proteinuria 21/22 %, hypertension 25/19 %, haemorrhage 2/4 % and thromboembolic events 10/6 %, for elderly and < 70 years group, respectively. Conclusions. In routine clinical practice, the combination of bevacizumab and chemotherapy is effective and welltolerated regimen in elderly patients with metastatic colorectal cancer.
Ključne besede: metastatic colorectal cancer, bevacizumab, chemotherapy, elderly
Objavljeno v DiRROS: 30.04.2024; Ogledov: 186; Prenosov: 56
Celotno besedilo (620,74 KB)